NCT04460456: A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received prior therapies known to confer clinical benefit (unless ineligible) or refused to receive
Exclusions: Patients with untreated brain metastasis

Comments are closed.

Up ↑